Boundless Bio (BOLD)

• Market cap: $32.3M
• 1 day: -0.69%
• 5 days: -3.36%
• 1 month: -7.1%
• 3 months: 25.22%
• 6 months: 29.73%
• Year to date: 18.03%
• 1 year: -7.69%
• 5 years: -89.89%
• 10 years: -89.89%
• Sector: Healthcare
• Industry: Biotechnology

About: Boundless Bio Inc is a clinical-stage oncology company. It is focused on developing cancer therapeutics that address the unmet need in patients with oncogene-amplified tumors by targeting extrachromosomal DNA (ecDNA), a root cause of oncogene amplification observed in cancer patients. Using its proprietary Spyglass platform, the company identifies targets essential for ecDNA functionality, then designs and develops small-molecule drugs called ecDNA-directed therapies (ecDTx) to inhibit those targets. Its main ecDTx candidate under development, BBI-940, is a novel, oral, selective degrader that has demonstrated potent anti-tumor activity across a range of cancer cell lines and mouse xenograft models, including single-agent tumor regressions.

Employees: 28